Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Selcia Appoints Simon Saxby as CEO and Andreas Rummelt to its Board

Published: Thursday, February 24, 2011
Last Updated: Thursday, February 24, 2011
Bookmark and Share
Simon Saxby brings successful leadership and executive management experience to the role of Selcia’s CEO and Andreas is recognized as a global expert in drug development and will further enhance the strategic strength of Selcia’s Board.

Selcia, has appointed Simon Saxby as its Chief Executive Officer (CEO). He will assume his position in April and takes over from Dr Hans Fliri who retains his role as Chairman of the Board. Selcia also announce the appointment of Dr Andreas Rummelt as a Non-Executive Director.

Chairman Dr Hans Fliri said, "I am very pleased to announce our two high profile appointments. Simon Saxby, until recently CEO of Cobra Biomanufacturing PLC and who joined Selcia’s Board last year, brings successful leadership and executive management experience to the role of Selcia’s CEO. Andreas Rummelt, formerly CEO of Sandoz and a member of the Novartis Executive Committee was recently appointed as Partner and CEO of the Swiss management consulting firm InterPharmaLink AG. Andreas is recognized as a global expert in drug development and will further enhance the strategic strength of Selcia’s Board. Both Simon and Andreas have a wealth of international experience and connections in the pharmaceutical industry and this expertise will be highly significant as Selcia plans its growth and expansion in the future".

Commenting on his appointment as CEO, Simon Saxby said, “With the increasing trend of outsourcing in the pharmaceutical and biotech sectors, this is an exciting time to be joining Selcia. I welcome the opportunity to work with Selcia’s management team and scientists as we expand the business through strategic partnerships built around the provision of high value services to our important and valued customers”.

On joining the Board, Dr Andreas Rummelt said, “Selcia has a track record of providing excellent custom radiolabelling and drug discovery services. I am pleased to bring my drug development, contract manufacturing and partnering expertise to support Selcia’s management team. I look forward to working with the Board to help define Selcia’s strategy for further expansion in the rapidly changing life sciences sector”.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More Than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Selcia and Cantab Announce Drug Discovery Collaboration
Partnership to accelerate Cantab’s programme to develop improved antibiotics for multidrug resistant Gram-negative bacterial infections.
Thursday, September 05, 2013
Selcia Introduces New Prolyl Isomerase Screening Service
Selcia Limited has announced the launch of a new platform to enable drug discovery and development on the target family of peptidyl-prolyl cis-trans isomerases (“PPIases”).
Friday, February 01, 2013
Selcia and NeuroVive to Develop New Mitochondrial Medicines
Selcia Limited and NeuroVive Pharmaceutical AB have signed a research collaboration agreement to develop new medicines and drug compounds targeting mitochondrial physiology and pathophysiology.
Monday, October 10, 2011
Selcia and ExonHit Therapeutics Announce Successful Fragment Screening Collaboration
Successful completion of a drug discovery project with ExonHit Therapeutics using Selcia’s fragment screening technology.
Thursday, April 21, 2011
Selcia and Gilead Sciences Extend Liver Disease Drug Discovery Collaboration
Selcia Limited announced a drug discovery collaboration agreement with Gilead Sciences Inc. Selcia’s chemists and biologists will continue to provide integrated drug discovery services to support Gilead’s liver disease research programmes.
Tuesday, November 30, 2010
Convergence Pharmaceuticals and Selcia Announce Drug Discovery Collaboration Around Chronic Pain
Convergence Pharmaceuticals Limited, the new company focused on the development of novel and high value analgesic medicines, and Selcia Limited, a contract research organisation, today are pleased to announce that they have entered into a drug discovery collaboration to identify and develop high quality candidate molecules for the treatment of chronic pain.
Thursday, November 25, 2010
Simon Saxby Joins Board at Selcia
Selcia Limited, a leading provider of contract research services in 14-C custom radiolabelling, integrated drug discovery, fragment screening and medicinal chemistry today announced the high profile appointment of Simon Saxby to the Board as a non-executive director.
Monday, June 28, 2010
Scientific News
Breakthrough Flu Vaccine Inhibited by Pre-existing Antibodies
Universal truths – how existing antibodies are sabotaging the most promising new human flu vaccines.
Researchers Develop Software That Could Facilitate Drug Development
AptaTRACE can identify aptamers, potentially speed drug advancement.
Gene Therapy for Metabolic Liver Diseases
Researchers have tested gene therapy in pigs from hereditary tyrosinemia type 1, with corrected liver cells being transplanted into the diseased liver.
Zika Vaccine Candidates Show Promise
Two experimental vaccines have shown promise against a major viral strain responsible for the Brazilian Zika outbreak.
New Medication Shows Promise Against Liver Fibrosis in Animal Studies
Liver fibrosis is a gradual scarring of the liver that puts people at risk for progressive liver disease and liver failure.
Raw Eggs Deemed Safe to Eat
A report published today by the Advisory Committee on the Microbiological Safety of Food (ACMSF) into egg safety has shown a major reduction in the risk from salmonella in UK eggs.
Monitoring TTX Toxin in Shellfish
In a number of small studies, mussels and oysters from the eastern and northern part of the Oosterschelde in Holland were found to contain tetrodotoxin (TTX).
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
NIH Begins Yellow Fever Vaccine Trial
NIH has initiated an early-stage clinical trial of a vaccine to protect against yellow fever.
Gene-Editing 'Toolbox' Targets Multiple Genes Simultaneously
Researchers have designed a system that modifies, or edits, multiple genes in a genome at once while minimising unintentional effects.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!